These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

259 related items for PubMed ID: 35570242

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Healthcare resource utilization and costs among patients with psoriasis treated with ixekizumab or adalimumab over 2 years of follow-up in real-world settings.
    Blauvelt A, Shi N, Murage MJ, Kern SA, Somani N, Burge R, Ridenour TL, Lew CR, Zimmerman NM, Zhu B.
    J Med Econ; 2022; 25(1):741-749. PubMed ID: 35615978
    [Abstract] [Full Text] [Related]

  • 6. Comparing Achievement of National Psoriasis Foundation Treatment Targets among Patients with Plaque Psoriasis Treated with Ixekizumab versus Other Biologics in Clinical and Real-World Studies.
    Armstrong A, González-Cantero A, Khattri S, Muzy G, Malatestinic WN, Lampropoulou A, Feely M, See SK, Mert C, Blauvelt A.
    Dermatol Ther (Heidelb); 2024 Apr; 14(4):933-952. PubMed ID: 38521874
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Comparison of Real-World Costs, Healthcare Resource Utilization, and Comorbidity-Related Costs Between Ixekizumab and Secukinumab Among Biologic-Experienced Patients with Psoriasis Over 18 Months in the USA.
    Blauvelt A, Shi N, Somani N, Burge R, Zhu B, Ridenour T, Kern S, Lew C, Zimmerman N, Murage M.
    Clin Drug Investig; 2023 Mar; 43(3):185-196. PubMed ID: 36840815
    [Abstract] [Full Text] [Related]

  • 9. Comparison of Real-World Treatment Patterns Among Biologic-Experienced Patients with Psoriasis Treated with Ixekizumab or Secukinumab Over 18 Months.
    Blauvelt A, Shi N, Burge R, Somani N, Ridenour TL, Zhu B, Atiya B, Lew CR, Zimmerman NM, Murage MJ.
    Dermatol Ther (Heidelb); 2021 Dec; 11(6):2133-2145. PubMed ID: 34652590
    [Abstract] [Full Text] [Related]

  • 10. Greater cumulative benefits from ixekizumab versus ustekinumab treatment over 52 weeks for patients with moderate-to-severe psoriasis in a randomized, double-blinded phase 3b clinical trial.
    Blauvelt A, Lomaga M, Burge R, Zhu B, Shen W, Shrom D, Dossenbach M, Pinter A.
    J Dermatolog Treat; 2020 Mar; 31(2):141-146. PubMed ID: 30799638
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Psoriasis treatment patterns and outcomes with ixekizumab in a real-world setting: results from a single US dermatology referral practice.
    Leonardi C, Tao R, Setayeshgar S, Wang S, Burge R, Zhu B, Malatestinic WN.
    J Dermatolog Treat; 2022 Jun; 33(4):2278-2284. PubMed ID: 34236934
    [Abstract] [Full Text] [Related]

  • 14. Adherence, persistence and treatment switching in psoriasis.
    Santoleri F, Musicco F, Fulgenzio C, Abrate P, Pestrin L, Pasut E, Modesti G, Giannini R, Rosa S, Piccoli M, Mingolla G, Zuzolo E, Gazzola P, Roperti M, Pieri G, Montresor V, Martignoni I, Gambera M, Langella R, Tinari G, Spoltore C, Roberti C, Fabio LD, Grossi L, Guarino F, Vita F, Lasala R, Costantini A.
    Immunotherapy; 2024 Jun; 16(9):611-621. PubMed ID: 38651935
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Switching biologics in children with psoriasis: Results from the BiPe cohort.
    Phan C, Beauchet A, Reguiai Z, Severino-Freire M, Mazereeuw-Hautier J, Bursztejn AC, Barbarot S, Hadj-Rabia S, Girard C, Phan A, Lacour JP, Lasek A, Abasq C, Brenaut E, Perrussel M, Droitcourt C, Mallet S, Piram M, Fougerousse AC, Barthélémy H, Balguérie X, Mahé E, Groupe de Recherche de la Société Française de Dermatologie Pédiatrique, the Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie.
    Pediatr Dermatol; 2022 Jan; 39(1):35-41. PubMed ID: 34888920
    [Abstract] [Full Text] [Related]

  • 18. Characteristics and Medication Use of Psoriasis Patients Who May or May Not Qualify for Randomized Controlled Trials.
    Malatestinic W, Nordstrom B, Wu JJ, Goldblum O, Solotkin K, Lin CY, Kistler K, Fraeman K, Johnston J, Hawley LL, Sicignano N, Araujo A.
    J Manag Care Spec Pharm; 2017 Mar; 23(3):370-381. PubMed ID: 28230450
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.